An ongoing dialogue on HIV/AIDS, infectious diseases,
May 27th, 2010
HIV Treatment is Prevention!
The Lancet has just published a large prospective study demonstrating the protective effect of HIV treatment on the risk of viral transmission:
3381 couples were eligible for analysis … Only one of 103 genetically-linked HIV-1 transmissions was from an infected participant who had started ART, corresponding to transmission rates of 0·37 (95% CI 0·09—2·04) per 100 person-years in those who had initiated treatment and 2·24 (1·84—2·72) per 100 person-years in those who had not—a 92% reduction (adjusted incidence rate ratio 0·08, 95% CI 0·00—0·57, p=0·004).
A similar observation was made in an earlier study presented at CROI 2009, not yet published. Astoundingly, the rate of transmission in this Lancet paper could have been be zero if analyses were limited only to those with undetectable viral loads on treatment.
So here’s the bottom line: HIV treatment dramatically, hugely, ginormously reduces the risk of HIV transmission.
(My daughter several years ago predicted that ginormous would become a word. She was right.)
Yes, we can quibble with some of the details — the 2009 study did not include viral load measurements, this one in the Lancet was actually part of a study of HSV treatment hence the results are observational, protection from infection is not 100% — but is there any doubt that HIV treatment is currently our most effective way of preventing the spread of HIV?
Some will say that the definitive study on this issue is HPTN 052, which randomizes the HIV-infected member of a serodiscordant couple to go on treatment or to wait until the CD4 cell count drops below 250. The primary endpoint is the rate of infection among the seronegative partners.
But that study is likely to exclude those most likely to transmit HIV, since it’s limited to people with HIV who have no symptoms, a relatively high CD4 cell count, and hence on average a lower viral burden.
At this point, it seems a no-brainer to me. Treatment is prevention.
Categories: HIV, Infectious Diseases, Patient Care, Research
Tags: antiretroviral therapy, CROI, HIV, HPTN 052, Lancet, prevention
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
4 Responses to “HIV Treatment is Prevention!”

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
- When AI Gets the Medical Advice Wrong — and Right
- ID Things to Be Grateful for — 2025 Edition
- What Use Is the Physical Examination in Current Medical Practice?
- Dengue, Malaria, HIV Cure, and Others — First Cold Snap of the Winter ID Link-o-Rama
- SNAP Trial Helps Resolve Long-Running Controversies Over Management of Staph Bacteremia
-
From the Blog — Most Recent Articles
- What Use Is the Physical Examination in Current Medical Practice? December 17, 2025
- Dengue, Malaria, HIV Cure, and Others — First Cold Snap of the Winter ID Link-o-Rama December 10, 2025
- ID Things to Be Grateful for — 2025 Edition November 24, 2025
- When AI Gets the Medical Advice Wrong — and Right November 18, 2025
- Hot Takes from IDWeek: CDC, COVID, and Two Doses of Dalbavancin November 13, 2025
FROM NEJM — Recent Infectious Disease Articles- Interactive Perspective: Measles December 18, 2025This Double Take video reviews evidence-based recommendations on measles prevention and management and explores commonly asked questions about the measles virus and infection.
- Noninferiority of One HPV Vaccine Dose to Two Doses December 18, 2025In this trial, one dose of an HPV vaccine was noninferior to two doses in preventing HPV type 16 or 18 infection.
- From Crisis to Action — Policy Pathways to Reverse the Rise in Congenital Syphilis December 18, 2025In recent years, cases of congenital syphilis have surged. This trend reflects both prenatal care gaps and systemic issues, including failures in testing, treatment, and public health infrastructure.
- Contact Precautions for MRSA and Vancomycin-Resistant Enterococcus December 18, 2025This feature about the use of contact precautions in the hospital for patients with MRSA or VRE offers a case vignette accompanied by two essays, one supporting continuing the use of contact precautions and the other recommending discontinuing them.
- Evidence to Action — Single-Dose HPV Vaccination and Cervical HPV Infection December 18, 2025Kreimer and colleagues now report in the Journal1 the results of the ESCUDDO trial, which showed that the efficacy of a single dose of either a bivalent human papillomavirus (HPV) vaccine or a nonavalent formulation was similar to that of the standard two-dose schedule. This randomized trial...
- Interactive Perspective: Measles December 18, 2025
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster

This is revolutionary discovery that can extinguish the epidemic if we can provide cheap, instant rapid accurate self-administered ID of new HIV infection along with 24/7 cheap access to first line therapy.
Yep. Big ifs there, I acknowledge.
But something like this seems to be happening within certain communities — MSM in San Francisco and injection drug users in Vancouver. With a higher proportion on treatment, there’s a suggestion that incidence is declining.
In our clinic here in Nigeria, we have experienced 100% success rates in prevention of transmission in serodiscordant couples who want to get pregnant without access to high tech methods. We just advocate the couple to wait till infected partner has an undetectable viral load and they have unprotected sex or with the condom slit at the tip during the woman’s fertile period. If only we can assure cheap, properly monitored undisrupted treatment…
I appreciate your highlighting this important study. It is my sense that people who successfully access and sustain treatment with ART are different in many ways. I advocate for universal access to care and ART is part of that, but I wonder if the results will be sustained with all persons–I hope so, but I wonder.